France

On September 11, 2026, the French National Authority for Health (HAS) published its favorable opinion on the coverage of the SAPIEN M3 transcatheter mitral valve replacement system under the Forfait innovation program.

In August 2026, the French National Authority for Health (HAS) published new recommendations on the registration of medical devices and medical aids in the List of Reimbursable Products and Services (LPPR) following its meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). One favorable opinion was issued supporting add-on reimbursement for a new cardiovascular device.

In July 2026, the French National Authority for Health (HAS) updated its guidance on submitting dossiers for an economic opinion by the Economic and Public Health Evaluation Commission (CEESP). The update includes a procedural guide on pre-submission meetings with the HAS Economic Evaluation Service. These meetings are intended to help manufacturers identify the most appropriate methodological choices and prepare economic evaluations that are consistent with HAS recommendations.

On August 6, 2026, the French Ministry of Health published the instruction for the 2026/27 application campaign for coverage with evidence development programs. The instruction outlines the research priorities, eligibility criteria, application procedures, and timelines for the different programs, including PHRC, PRME, PREPS, PHRIP, and PRT.

In July 2026, the French National Authority for Health (HAS) published new recommendations on the registration of medical devices and medical aids in the List of Reimbursable Products and Services (LPPR) following its meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). Favorable opinions were issued supporting add-on reimbursement for one new device and an extension of the reimbursed indications for another, in the gastrointestinal and peripheral vascular fields.

In July 2026, the French Ministry of Health granted early coverage under the PECAN scheme to a digital medical device (Poppins Clinical) for the rehabilitation of specific learning disorders involving reading deficits. Since the scheme's inception in 2023, all devices granted early coverage have been intended for remote patient monitoring. The decision on Poppins Clinical marks the first PECAN coverage of a therapeutic digital medical device.

In July 2026, the French National Authority for Health established MiMED department within its Directorate for Evaluation and Access to Innovation. The new department will modernize health technology assessment methods, strengthen the use of real-world data, and support France's contribution to European HTA coordination.

In June 2026, the French National Authority for Health (HAS) published new recommendations on the registration of medical devices and medical aids in the List of Reimbursable Products and Services (LPPR) following its meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). Favourable opinions were issued on the add-on reimbursement for 14 new devices and on the extension of indications for one device, in different medical fields.

On June 2, 2026, the Decision of the National Union of Health Insurance Funds (UNCAM) updating the Nomenclature of Medical Biology Procedures (NABM) was released. The NABM is France’s primary permanent reimbursement catalog for in-vitro diagnostic tests covered under statutory health insurance. The update introduces regular reimbursement for four new codes, including two next-generation sequencing (NGS) panels that were previously covered temporarily under the innovative payment scheme (RIHN framework).

In May 2026, the French National Authority for Health (HAS) published new recommendations on the registration of medical devices and medical aids in the List of Reimbursable Products and Services (LPPR) following its meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). Favorable opinions were issued for the add-on reimbursement of two new devices. Opinions concerned orthopedics and the peripheral vascular fields.

On May 20, 2026, the French Ministry of Health published the Decree, establishing a phase-out mechanism for older medical telemonitoring activities reimbursed via LATM when a newer, superior solution is registered for the same indication. Older solutions are subject to a 36-month transitional period before the removal, with three successive annual tariff reductions of 10% vs. the tariff of the newly registered solution.

In April 2026, the French Ministry of Health published an update to the 2026 List of Innovative Procedures Outside the Nomenclature (LAHN), which includes innovative IVD tests temporarily funded under the RIHN framework. The update introduced two new “duplicative” codes in the field of cytogenetics that are exempt from the tariff reduction mechanism.